FIELD: organic chemistry.
SUBSTANCE: present invention relates to organic chemistry, namely to a method for producing 1-(1,3-dioxolanyl-2-methyl)-3,5,7-triaza-1-azoniatricyclo[3.3.1.13,7]decane bromide. The method involves the interaction of urotropin with 2-bromomethyl-1,3-dioxolane at a temperature of 60°C for 4 hours at the following ratio of components, mol%: urotropin - 50; 2-bromomethyl-1,3-dioxolane - 50.
EFFECT: invention is aimed at obtaining a compound 1-(1,3-dioxolanyl-2-methyl) -3,5,7-triaza-1-azoniatricyclo [3.3.1.13,7] decane bromide, which has antitumor activity.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT BASED ON ARGLABIN DERIVATIVE, HAVING SELECTIVE CYTOTOXIC ACTION | 2023 |
|
RU2814738C1 |
| AGENT BASED ON ARGLABIN DERIVATIVE, HAVING SELECTIVE CYTOTOXIC ACTION | 2023 |
|
RU2814259C1 |
| ARGLABIN DERIVATIVES WITH SELECTIVE CYTOTOXIC EFFECTS | 2023 |
|
RU2805915C1 |
| NEW STERICALLY HINDERED PHENOLS CONTAINING BENZOFUROXAN FRAGMENTS WITH ANTITUMOR ACTIVITY | 2022 |
|
RU2796810C1 |
| NEW SIGMA (Σ)-RECEPTOR LIGANDS WITH ANTIAPOPTOTIC AND/OR PROAPOPTOTIC PROPERTIES IN RELATION TO BIOCHEMICAL MECHANISMS OF CELL, POSSESSING NEUROPROTECTIVE, ANTICANCER, ANTIMETASTATIC AND ANTI-INFLAMMATORY ACTION IN CHRONIC INFLAMMATORY PROCESS | 2008 |
|
RU2497511C2 |
| BROMINE-CONTAINING STERICALLY HINDERED PHENOLS WITH ANTICANCER ACTIVITY | 2023 |
|
RU2822270C1 |
| PHARMACEUTICAL COMPOSITION, CONTAINING ANTAGONIST P2X OF RECEPTOR AND FACTOR OF TUMOUR NECROSIS α | 2004 |
|
RU2350354C2 |
| ANTITUMOR AGENTS BASED ON MACRO- AND MICROELEMENT-CONTAINING POLYGALACTURONATES (OPTIONS) | 2022 |
|
RU2792613C1 |
| BIS-(PHENYL)-ETHANE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1992 |
|
RU2118311C1 |
| SODIUM COBALT POLYGALACTURONATE WITH ANTITUMOR ACTIVITY | 2023 |
|
RU2794885C1 |
